Clinical trials: Covid-19 Patients
Covid19
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
This is an interventional, multicenter, 2-arm, parallel-group, randomized, double-blind, placebo controlled, dose-escalation, safety and efficacy study of F-652 treatment versus placebo in patients aged 18 years or older with a…
- Trial name
- NCT04498377
- Testing
- F-652
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EVIVE Biotechnology
SARS-CoV-2 Acute Respiratory Disease, Covid19
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality.
- Trial name
- STC-19 (NCT04371471)
- Testing
- STC-19 score
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Postural Orthostatic Tachycardia Syndrome
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic…
- Trial name
- POTS (NCT05633407)
- Testing
- Efgartigimod
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- argenx
COVID-19 Infection
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study.
- Trial name
- E-APLICOV-PC (NCT05121740)
- Testing
- Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- PharmaMar
Dysosmia, Anosmia
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
This research study is a randomized controlled trial in pediatric and young adult patients who have lost their sense of smell due to COVID-19 viral infection. The goals are: 1.
- Conditions
- Dysosmia, Anosmia, Covid19
- Trial name
- NCT04964414
- Testing
- Smell Retraining, Budesonide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Amanda Stapleton
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
COVID-19, SARS-CoV-2
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not…
- Trial name
- ACTION (NCT04332107)
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- Thomas M. Lietman
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
Covid19, Respiratory Function Loss
Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
COVID-19 infection is the cause of the current pandemic, responsible for loss of life and disability at a rate unseen before. Among survivors, the infection may cause lasting damage, such as permanent loss of lung function.
- Conditions
- Covid19, Respiratory Function Loss, Coronavirus Infection, Pneumonia, Viral
- Trial name
- NCT04826731
- Testing
- Incentive Spirometer/Respiratory Exerciser
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Diskapi Yildirim Beyazit Education and Research Hospital
Corona Virus Infection
Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients
Treatment with glucocorticoids in COVID patients. Low-intervention, phase IV, open-label, randomised, low-intervention clinical trial comparing 2 active treatments.
- Trial name
- NCT04780581
- Testing
- Dexamethasone, Methylprednisolone
- Where
- 4 sites in Spain
- Volunteers
- 128 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Long COVID, Cardiorespiratory Fitness
Nitrite Supplementation in Long COVID Patients
Potential benefits of a nitrate-rich juice supplement to improve skeletal muscle function and associated physical capacity will be studied in patients with Long COVID.
- Trial name
- NCT05618574
- Testing
- 140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- VA Office of Research and Development
Covid-19, SARS-CoV2
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia.
- Trial name
- COVA (NCT04472728)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 238 people
- Sponsor
- Biophytis
COVID-19
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm).
- Trial name
- COLHEART-19 (NCT04355143)
- Testing
- Colchicine Tablets, Current care per UCLA treating physicians
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- University of California, Los Angeles
Covid19
Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)
This is an open-label unblinded, randomized study to treat hospitalized covid-19 patients with colchicine plus current care (per institution treating physicians) vs.
- Trial name
- Colheart-19 (NCT04762771)
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Baptist Health South Florida
COVID-19
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
Introduction: Corona Virus induced disease - 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now.
- Trial name
- NCT05502081
- Testing
- Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir
- Where
- Egypt
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Confirmed Coronavirus Disease
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e.
- Trial name
- NCT04530136
- Testing
- Ruconest
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pharming Technologies B.V.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
COVID-19
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780437
- Testing
- AZD7442, Remdesivir
- Where
- 124 sites in United States, Denmark and 7 more
- Volunteers
- 1,455 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)